- About us
- Clinical trials
- News & Publications
Martin Steegmaier graduated from the Northern Arizona University. He earned his Ph.D. in biochemistry from the University of Basel, Switzerland. In addition, Martin received an MBA from the Edinburgh Business School (UK). He spent 4 years as a postdoctoral fellow at Stanford University Medical School.
In 2000, Martin joined Boehringer Ingelheim’s Oncology Drug Discovery Department and held positions with increasing responsibility advancing first-in-class oncology projects into the clinic. Martin joined Roche in 2006 in Basel and held various positions in Pharma Partnering and in the Oncology disease area. In 2012, Martin became the Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center Munich site with the responsibility to generate and profile novel therapeutic antibodies for different disease areas. In March 2020, Martin became Head of Research at MorphoSys in Planegg Munich, Germany (FSE & NASDAQ: MOR) focusing on the generation of differentiated, more efficacious and safer antibody-based therapeutics in the area of immuno-oncology and hematology-oncology.
Martin Steegmaier joined SOTIO in 2022 as Chief Scientific Officer.